E-mail

E-mail a Wiley Online Library Link

Eunice L. Kwak, Geoffrey I. Shapiro, Seth M. Cohen, Carlos R. Becerra, Heinz-Josef Lenz, Wen-Fang Cheng, Wu-Chou Su, Meghan Robohn, Florence Le Maulf, Maximilian T. Lobmeyer, Vikram K. Chand and A. John Iafrate Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation Cancer 119

Version of Record online: 14 JUN 2013 | DOI: 10.1002/cncr.28120

In this phase 2, open-label, exploratory trial, single-agent afatinib, an irreversible ErbB Family Blocker, demonstrates limited yet encouraging activity with manageable tolerability in multiple histologies of solid tumors (excluding lung cancer) in patients who were screened prospectively for EGFR/HER2 gene amplification or EGFR-activating mutations. The early termination of this study because of recruitment challenges highlights the need for alternative approaches in biomarker-driven patient selection in this setting.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field

SEARCH